Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Cytokeratin and mammaglobin as tumor markers in patients with high risk breast cancer

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Breast Cancer Research20002 (Suppl 1) :P7.05

https://doi.org/10.1186/bcr172

  • Published:

Keywords

  • Breast Cancer
  • Risk Breast Cancer
  • Prognostic Relevance
  • Cell Collection
  • Internal Sequence

Aims of the study

To investigate the incidence and prognostic relevance of tumor micro-contamination in BM and/or G-CSF-mobilized peripheral blood progenitor cells collections of stage II-III breast cancer patients.

Patients and methods

Patients were enrolled from September 1998 through May 1999 and underwent high-dose chemotherapy with autologous PBPC transplantation. We analysed a total of 71 patients for TC on PBPC apheresis (28 of them had previously frozen samples). 43/71 patients also had their BM evaluated on the day of the first PBPC collection after 5 days of G-CSF administration (BM-STIM) and immediately before HDCT (BM-PRECT). Cytokeratin (CK) expression was evaluated in all samples by either immunocytochemistry (ICC, sensitivity 1 × 10-6 cells, 9-16 × 10-6 cells for each sample) and reverse transcriptase nested PCR (RT-PCR, sensitivity 1 × 10-7cells). Amplified products were then annealed to a 32P-labelled internal sequence probe to confirm specificity. 41 patients were also evaluated by nested RT-PCR for Mammaglobin (MAM, sensitivity 1 × 10-6 cells) gene expression.

Results

(1) PBPC frequency of CK+ was 11% by ICC and 66% by RT-PCR on 71 patients' samples; (2) BMSTIM and BMPRECT frequency of CK+ was 7-14% by ICC and 60-65% by RT-PCR on 43 patients' samples; (3) all CK ICC+ samples were MAM RT-PCR+; (4) 53% of patients with CK RT-PCR+ BM-STIM had their PBPC and BM-PRECT CK RT-PCR+; (5) after a median follow-up of 21 months on 28 patients with frozen samples, 25% of patients relapsed and 43% of them had contaminated PBPC; (6) 74% of CK ICC+ samples were CK RT-PCR+; (7) BMSTIM, PBPC and BMPRECT frequencies of MAM+ were 15, 17 and 22% respectively by RT-PCR on 41 patients' unfrozen samples; (8) PBPC frequency of MAM+ was 20% by RT-PCR on 25 patients' frozen samples.

Conclusion

(1) MAM gene evaluation could add a lot of sensitivity and specificity to the overall results. (2) G-CSF administration for PBPC mobilization does not increase PBPC contamination. (3) A longer follow-up of these patients is needed to evaluate the prognostic relevance of different markers of tumor cell contamination in HDCT for breast cancer.

Authors’ Affiliations

(1)
European Institute of Oncology, Milan, Italy

Copyright

© Current Science Ltd 2000

Advertisement